13 April 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Venetoclax (Venclyxto)
  
• Idelalisib (Zydelig)
  
• Ibrutinib (Imbruvica)
  
• Desmopressin acetate (Nocdurna)
  
• Pembrolizumab (Keytruda)
  
• Nivolumab (Opdivo)
  
• Guanfacine hydrochloride (Intuniv)
  
• Ethinyloestradiol with norethindrone acetate (Estrostep)
  

Read TC agenda [French]